A prospective, randomised, double blind, placebo-controled, multi-centre trial to assess safety, efficacy, tolerability and immunogencity of influenza virus vaccine, trivalent types A & B, live cold-adapted, liquied formulation (CAIV-T), administered concomitantly with a combination live, attenuated, mumps, measles, and rubella vaccine in healthy children aged 11-24 months

Simple item page
dc.contributor.authorBreiman, Robert F.
dc.date.accessioned2014-06-01T04:20:43Z
dc.date.available2014-06-01T04:20:43Z
dc.date.issued2002
dc.identifier.otherhttp://dspace.icddrb.org/jspui/handle/123456789/5029
dc.identifier.urihttp://hdl.handle.net/123456789/5029
dc.language.isoen
dc.publisherDhaka: International Centre for Diarrhoeal Diseases Research, Bangladesh; 2002
dc.sourceICDDR,B Institutional Repository
dc.subjectClinical protocols
dc.subjectVaccination
dc.subjectOrthomyxoviridae
dc.titleA prospective, randomised, double blind, placebo-controled, multi-centre trial to assess safety, efficacy, tolerability and immunogencity of influenza virus vaccine, trivalent types A & B, live cold-adapted, liquied formulation (CAIV-T), administered concomitantly with a combination live, attenuated, mumps, measles, and rubella vaccine in healthy children aged 11-24 months
dc.typeOther

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
ICDDRBProtocol-2002-012.pdf
Size:
3.48 MB
Format:
Adobe Portable Document Format
Download

Collections

Infectious diseases and vaccine sciences research protocols